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ABSTRACT   Here, we report on four cases of gastric cancer in patients with autoimmune 
gastritis (AIG). AIG is characterized by the corpus-predominant atrophic gastritis with preserved 
antrum caused by autoimmune mechanisms. Although AIG is a high risk factor for gastric 
cancer and neuroendocrine tumors (NET), there are few reports describing the characteristics of 
gastric cancer in patients with AIG. In this case report, all four cases were diagnosed as having 
AIG by endoscopic findings and the presence of extra-gastric autoimmune diseases before the 
treatment for gastric cancer. doi：10.11482/KMJ-E201945075　(Accepted on June 14, 2019)
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〈Case Report〉
INTRODUCTION
   Autoimmune gastritis (AIG), also known as type 
A gastritis, is characterized by atrophic changes 
in the fundic mucosa. It is caused by autoimmune 
mechanisms, such as anti-parietal cell antibodies 
(PCA), which lead to hypergastrinemia and 
cause hyperplasia of enterochromaffin-like cells, 
resulting in complications such as hyperplastic 
polyps, neuroendocrine tumors (NETs), and gastric 
cancer１－６）.  AIG is commonly diagnosed via 
medical examination of patients with pernicious 
anemia (PA) or type-1 NETs, and it is associated 
with autoimmune thyroid disease７，８） or type-I 
diabetes mellitus (DM)９，10）. In Japan, AIG is 
thought to be a rare disease11） and there is no 
data about the prevalence of AIG because it is 
asymptomatic in its initial stage. In its late stage, 
AIG might cause PA characterized by megaloblastic 
anemia and be diagnosed in clinical practice. 
In previous clinical statistical data gathered by 
Sugihara T and Yawata Y, the estimated prevalence 
of PA caused by AIG was 0.34 to 0.5 per 100,000 
people in Japanese12）. Recently we diagnosed 
four cases of gastric cancer in patients with AIG 
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our Department of Surgery for gastric cancer surgery. 
This patient had a history of hypothyroidism and 
atrial fibrillation. An esophagogastroduodenoscopy 
revealed a type 0-IIc+IIa gastric cancer in the lesser 
body and severe atrophic gastritis in the fundus, 
whereas no atrophic change was seen in the antrum 
(Fig. 1,2 and 3). The fasting gastrin level was 1,954 
pg/ml (normal range; 5 - 150 pg/ml) and ECMs 
were documented in the corpus after the surgical 
operation.
Case 2. 
   An esophagogastroduodenoscopy was performed 
on an 83-year-old Japanese woman due to increased 
CA19-9 levels and revealed type 1 gastric cancer in 
the lesser antrum and corpus-predominant atrophic 
gastritis (Fig. 4,5 and 6). The patient had a history 
of type 1 diabetes mellitus (DM), hypothyroidism 
and renal failure. The fasting gastrin level was 6,333 
pg/ml and ECMs were documented in the corpus 
after the surgical operation.
Cases 3 and 4. 
   These two cases both had a history of type C 
hepatitis and hepatocellular carcinoma (HCC) and 
were diagnosed with early gastric cancer after an 
examination of the esophageal varix. Both cases 
were completely resected by endoscopic therapy. 
The fasting gastrin level was 7,445 pg/ml in case 3 
and 2,848 pg/ml in case 4. PCA was positive in both 
cases.   
DISCUSSION
   In this case report, AIG was diagnosed based 
between April 2015 and December 2018. Because 
AIG is thought to be a rare disease in Japan, we 
are reporting on the clinical characteristics that we 
observed with an emphasis on endoscopic findings 
and also on the history of using the presence of 
autoimmune diseases to diagnose AIG. The presence 
of ECM（composed of hyperplastic ECL cells）
is one of characteristic histologic findings of AIG, 
and immunohistochemically can be detected by 
chromogranin A antibody (neuroendocrine marker).
   In this study, we defined AIG as the presence 
of corpus-predominant atrophic gastritis with 
hypergastrinemia and PCA and/or the presence 
of endocrine cell micronest (ECM) in the corpus 
mucosa. 
CASE REPORT
   The characteristics of four cases of gastric cancer 
developed from AIG are shown in the Table 1. 
Three were females and all were over 75 years old. 
Three cases located in the antrum were diagnosed 
at an early stage. Histology of the gastric cancer 
indicated well-differenciated adenocarcinoma in 
two cases, signet-ring cell carcinoma in one, and 
mucinous adenocarcinoma in one. All four cases had 
multiple hyperplastic polyps in the corpus. ECMs 
in the corpus were documented in three cases (cases 
1, 2, and 4, Fig. 1-6). Cases 3 and 4 were tested for 
PCA and the results were positive. Intrinsic factor 
antibody was not tested for in any of the cases and 
none of the cases were shown to have PA. 
Case 1. 
   An 83-year-old Japanese woman was referred to 
Table 1. Characteristics of four cases of gastric cancer developed from AIG
No. Age Sex Type Location of tumor Depth Histology Gastrin(pg/ml) ECM
Co-existing 
lesions  
1 83 F 0-IIc+IIa Lesser corpus SM2 sig > muc > por 1954 + HP
2 84 F 1 Lesser antrum MP muc > tub1 6334 + HP
3 80 M 0-I Anterior antrum M tub1 7445 NT HP
4 75 F 0-IIa Posterior antrum M tub1 2848 + HP
AIG; Autoimmune gastritis, ECM; Endocrine cell micronest, NT; Not tested, HP; Hyperplastic polyps




Fig. 1. Endoscopic feature of case 1.
A: Corpus of the stomach; B: type0-IIc tumor located in the lessor antrum; C: Antrum, D: Fornix and corpus The gastroscopy 
shows severe atrophic gastritis demonstrating disappearing of the visible vascular patterns and the giant rugae in the corpus and 
body of the stomach (A,D), whereas no atrophic change is seen in the antrum (C).
Fig. 2. Gross and histological findings of case 1.
A. A gross figure of stomach showing Type 0-IIc+IIa gastric cancer (arrow) is located in the lesser body, and severe atrophic 
gastritis in the fundus is found, whereas no atrophic change is seen in the antrum. A hyperplastic polyp (arrowhead) is found in 
the posterior wall.  B. Close-up picture of Type 0-IIc+IIa gastric cancer (27x14mm in size)  C. (Hematoxylin-eosin、10x4) The 
gastric cancer with mucin production is seen in the gastric mucosa spreading to submucosa. D. (Hematoxylin-eosin、10x60) 
Many signet ring cells (arrows) are seen in the mucinous matrix. E. (Hematoxylin-eosin、10x20) A hyperplastic polyp is 






Fig. 3. Chromogranin A staining of atrophic gastric mucosa.   
Arrows indicate endocrine cellular micronests (ECMs) are positive for chromogranin A. Figure 3. 




Fig. 4. Endoscopic features of case 2.
A: Corpus of the stomach; B: type 1 tumor located in the lessor antrum; C: Antrum, D: Fornix/cardia　Almost same findings of 
severe atrophic gastritis as in Figure 1 are confirmed in A-D. 
Fig. 5. Gross and histological findings of case 2.
A: Gross figure of stomach shows Type 1 gastric cancer located in the lesser antrum and corpus with severe atrophic gastritis. 
B. The cut surface of the tumor shows a tumor containing abundant mucinous element. C. A lupe figure shows the tumor with 
two components of mucinous carcinoma (muc) containing signet ring cell carcinoma (sig) and tubularadenocarcinoma (tub1). 
D. (Hematoxylin-eosin、10x40)  Mucinous carcinoma is composed of signet ring cell carcinoma (sig, arrows) and abundant 
mucinous matrix (muc). E. (Hematoxylin-eosin, 10x20) Tubular adenocarcinoma (tub1) shows well differentiated tubular 
structures. Gross findings: Type 1 gastric cancer is located in the lesser antrum, and corpus with severe atrophic gastritis was 
found. Microscopic findings: The cancer was composed with two components (arrows), mucinous adenocarcinoma (muc) with 













Fig. 6. Chromogranin A staining of atrophic gastric mucosa.
Immunohistochemical staining (Chromogranin A, 10x20), Arrows indicate endocrine cell 
micronests (ECMs) with chromogranin A. 
Figure 6.  
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on endoscopic findings (corpus-predominant 
atrophic gastritis, the presence of multiple gastric 
hyperplastic polyps), and the coexistence of extra-
gastric autoimmune diseases (hypothyroidism and 
type 1 diabetes mellitus) at the time of the gastric 
cancer diagnosis. AIG is characterized by the 
presence of severe corpus-predominant atrophic 
gastritis with hypergastrinemia and PCA and/or the 
presence of ECM in the corpus mucosa, while also 
being known as a high risk for gastric cancer and 
NET１－６）. 
   In our previous study, patients with a fasting 
gastrin level of ≥  245.1 pg/mL were considered as 
having hypergastrinemia13）. In this report, extremely 
high gastrin levels were found in all four cases 
(1,954 pg/ml, 6,334 pg/ml, 7,445 pg/ml, and 2,848 
pg/ml). Because gastrin is known to be a growth 
factor for gastric cancer and NET14－17）, extreme 
hypergastrinemia may have played a role in the 
carcinogenesis in these four cases.
   In this case report, three of the four cases were 
polypoid type gastric cancer and the remaining one 
had polypoid components in the gastric lesion. Our 
previous study of 957 patients with early gastric 
cancer indicated that serum gastrin levels were 
significantly higher in patients with elevated tumors 
than in patients with depressed tumors and have 
the possibility to enact morphological change in 
the gastric cancer through the gastrin receptor18）. 
Therefore, the determination of gastrin levels 
contributes not only to the diagnosis of AIG but also 
to the pathogenesis of gastric cancer.
   AIG is associated with extra-gastric autoimmune 
diseases such as autoimmune thyroid disease７，８） and 
type 1 DM９，10）. Two of our cases had hypothyroidism 
mainly caused by autoimmune thyroiditis, and one 
also had type 1 diabetes mellitus. The coexistence of 
at least two autoimmune-mediated endocrinopathies 
is known as polyglandular autoimmune syndrome 
(PSA), which was further classified into four 
types by Neufeld M and Blizzard R19－21）. Case 
1 had hypothyroidism and would be classified 
as APS type 3 (autoimmune thyroid disease + 
autoimmune gastritis). Case 2 could be called APS 
type 4 (autoimmune thyroid disease + type 1 DM + 
autoimmune gastritis). 
   Although APS is thought to be a rare disease, it 
is important to suspect APS in patients with one 
autoimmune disease. Even though two patients 
(cases 3 and 4) had HCC with type C hepatitis, 
no association between AIG and HCC has been 
previously reported. Because the presence of 
extra-hepatic malignancies is one important risk 
factor associated with the prognosis of HCC, a 
check for common malignancies, including gastric 
cancer, is important. Our two cases (case 3 and 
4) were diagnosed at an early stage without any 
gastrointestinal symptoms related to gastric cancer 
due to a follow-up endoscopy for the esophageal 
varix and could be completely treated by endoscopic 
therapy. 
   All four cases had multiple hyperplastic polyps 
in the corpus. It is important to determine the 
gastrin level for the screening of AIG in patients 
with gastric hyperplastic polyps because previous 
studies, including our own, have indicated that AIG 
is closely related to gastric polyps11，13，22，23）. Park JY 
et al. reported that there were 240 endoscopically 
or grossly identifiable lesions in the stomach in 
143 of 461 (31%) patients with AIG and the lesions 
consisted of 138 hyperplastic polyps22）. Zhang H. 
et al. also indicated in a study of 320 patients with 
AIG that 63 patients (19.7%) with AIG had gastric 
hyperplastic polyps23）. In addition, other previous 
studies have indicated that AIG is common in 
patients with gastric polyps and gastric polyps are 
common in patients with pernicious anemia, the late 
stage of AIG24）. 
   An early diagnosis of AIG may prevent the latent 
stage of this disease, pernicious anemia, due to 
vitamin B12 deficiency or peripheral neuropathy 
and may help identify patients at a high risk 
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for developing either gastric cancer or NET. As 
reported here, careful endoscopic observation of 
the gastric mucosa to identify corpus-predominant 
atrophic gastritis, gastric hyperplastic polyps and 
extra-gastric autoimmune diseases might help 
to diagnose AIG. Hemoglobin and MCV(Mean 
Corpuscular Volume) of our cases were 10.9 g/dl 
and 90.7fl in case 1, 10.2 g/dl and 97.2 fl in case 
2, 14.2 g/dl and 95.9 fl in case 3, 8.8g/dl and 88.5 
fl in case 4. Therefore, all four cases did not show 
the remarkable findings of pernicious anemia. The 
serum vitamin B12 level were not measured in all 
four cases. 
   Mahmud N et al. showed that AIG is associated 
with a high prevalence and incidence of gastric 
cancer, and endoscopic surveillance should be 
considered in all patients with AMAG, especially 
in patients with advanced age ( ≥  70 years). 
While endoscopic surveillance at 3 years appears 
reasonable, prospective cohort studies and cost 
effectiveness analyses are clearly needed to 
further define the estimated risk of cancer in 
patients with AIG and to refine recommended 
surveillance intervals25）. Park JY et al. indicated 
that the important clinical findings include anemia 
(microcytic or macrocytic) or endocrine dysfunction 
(diabetes mellitus, autoimmune thyroiditis)26）. 
Although pernicious anemia and AIG have been 
recognized for more than 100 years, it is still in the 
infancy of recognizing the early presentation of 
AIG and standardizing our management of these 
patients26). These suggestions are objectively 
appropriate.
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